Cancer immunotherapy: A treatment for the masses

被引：468

作者：

Blattman, JN

Greenberg, PD

机构：

[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA

[2] Univ Washington, Dept Immunol, Seattle, WA 98195 USA

[3] Univ Washington, Dept Med, Seattle, WA 98195 USA

来源：

SCIENCE | 2004年 / 305卷 / 5681期

关键词：

D O I：

10.1126/science.1100369

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Cancer immunotherapy attempts to harness the exquisite power and specificity of the immune system for the treatment of malignancy. Although cancer cells are less immunogenic than pathogens, the immune system is clearly capable of recognizing and eliminating tumor cells. However, tumors frequently interfere with the development and function of immune responses. Thus, the challenge for immunotherapy is to use advances in cellular and molecular immunology to develop strategies that effectively and safely augment antitumor responses.

引用

收藏

页码：200 / 205

页数：6

相关论文

共 45 条

[1] Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 [J].

Brentjens, RJ ;

Latouche, JB ;

Santos, E ;

Marti, F ;

Gong, MC ;

Lyddane, C ;

King, PD ;

Larson, S ;

Weiss, M ;

Rivière, I ;

Sadelain, M .

NATURE MEDICINE, 2003, 9 (03) :279-286

[2]

BURNET M, 1957, BRIT MED J, V5022, P779

[3] Improving the efficacy of antibody-based cancer therapies [J].

Carter, P .

NATURE REVIEWS CANCER, 2001, 1 (02) :118-129

[4] Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death [J].

Cheng, LE ;

Öhlén, C ;

Nelson, BH ;

Greenberg, PD .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (05) :3001-3006

[5] Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation [J].

Childs, R ;

Chernoff, A ;

Contentin, N ;

Bahceci, E ;

Schrump, D ;

Leitman, S ;

Read, EJ ;

Tisdale, J ;

Dunbar, C ;

Linehan, WM ;

Young, NS ;

Barrett, AJ ;

Clave, E ;

Epperson, D ;

Mayo, V .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (11) :750-758

[6] Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J].

Clynes, RA ;

Towers, TL ;

Presta, LG ;

Ravetch, JV .

NATURE MEDICINE, 2000, 6 (04) :443-446

[7]

Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514

[8] The three Es of cancer immunoediting [J].

Dunn, GP ;

Old, LJ ;

Schreiber, RD .

ANNUAL REVIEW OF IMMUNOLOGY, 2004, 22 :329-360

[9]

Ehrlich P., 1909, NED TIJDSCHR GENEES, V5, P273, DOI DOI 10.1101/833004

[10] Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy [J].

Engelhard, VH ;

Bullock, TNJ ;

Colella, TA ;

Sheasley, SL ;

Mullins, DW .

IMMUNOLOGICAL REVIEWS, 2002, 188 :136-146

← 1 2 3 4 5 →